Viana M B, Oliveira B M, Silva C M, Rios Leite V H
Hematology Division, Hospital das Clinicas, Belo Horizonte, Brazil.
Med Pediatr Oncol. 1991;19(4):289-94. doi: 10.1002/mpo.2950190414.
Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency. Complete response was observed in five. There was no major toxicity. Although three of four evaluable patients relapsed, the drug was considered useful in moving the children from a symptomatic to an asymptomatic clinical status. Etoposide may become a "first-line" drug in the treatment of systemic LCH, especially when the side effects of steroid therapy are considered unacceptable.
六名儿童接受依托泊苷单药治疗朗格汉斯细胞组织细胞增多症（LCH；组织细胞增多症X）。五名患儿诊断时年龄小于2岁。所有患儿均有多器官受累；一名患儿有肝肺功能障碍。两名婴儿还有免疫缺陷的临床体征。五名患儿出现完全缓解。未出现严重毒性反应。尽管四名可评估患者中有三名复发，但该药物被认为有助于使患儿从有症状的临床状态转变为无症状状态。依托泊苷可能会成为系统性LCH治疗的“一线”药物，尤其是当类固醇疗法的副作用被认为不可接受时。
